A comparison of HPLC and bioassay methods for plasma melanotan‐II (MT‐II) determination: Application to a pharmacokinetic study in rats

A comparison of HPLC and bioassay methods for plasma

The pharmacokinetic profile of the melanotropic peptide, melanotan-II (MT-II), was determined in rats following a 0.3 mg kg −1 intravenous dose. Regression analysis of the plasma MT-II concentrations determined using HPLC and bioassay methods indicated the existence of a significant linear correlation ( r = 0.90, p < 0.001).

Published in: Biopharmaceutics & Drug Disposition · 1994Authors: Sydney O Ugwu · James Blanchard · Linh D Nguyen · Mac E Hadley · Robert T DorrAffiliation: University of ArizonaAbout: Bioassay · Salientia · GRENOUILLE · Lactam · Correlation · High-performance liquid c…

A comparison of HPLC and bioassay methods for plasma

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: Application to a pharmacokinetic study in rats Article in Biopharmaceutics & …

Melanotan II pharmacokinetic – PubMed Result

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm Drug Dispos. …

Pharmacologic Response of a Controlled-Release PLGA

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm. Drug Dispos. 15 :383–390 (1994).

The protective effects of the melanocortin receptor (MCR

A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats. Biopharm Drug Dispos. 1994; 15 :383–390.

Determination of melanotan-II in rat plasma by liquid

A method is described for the determination of melanotan-II (MT-II), a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH), in rat plasma by liquid

Co-treatment with melanotan-II, a potent melanocortin

Cisplatin, an important chemotherapeutic agent, has severe dose-limiting side effects including peripheral neurotoxicity and ototoxicity. Peripheral neurotoxicity can be delayed or prevented by simultaneous treatment with a class of neuropeptides known as melanocortins.

Discovery and Development of Novel Melanogenic Drugs

Kreutzfeld, K. L., and Bagnara, J. T, 1989, Application of α-Melanocyte stimulating hormone (α-MSH) radioimmunoassay to the detection of the superpotent analog, [Nle 4, d …

Co-treatment with melanotan-II, a potent melanocortin

Examples are ORG 2766, α-melanocyte stimulating hormone (α-MSH) and melanotan-II (MT-II). In albino guinea pigs, our group has found that ORG 2766 and α-MSH can also reduce cisplatin-induced ototoxicity. In this study we investigated the possibly protective effects of MT-II upon cisplatin ototoxicity.

Published in: Hearing Research · 2002Authors: Francisca L C Wolters · Thijn F De Vocht · Sjaak F L Klis · Frank P T Hamers · Guido …About: Melanocortin · Neuropeptide · Cochlea · Toxicity · Compound muscle action potential

Pharmacologic response of a controlled-release PLGA

The objective of this study was to evaluate in vitro and in vivo the melanogenic activity of one-month duration Melanotan-I (MT-I) implants prepared using poly (D,L lactide-co-glycolide) polymer. The biological activity of the samples of MT-I

Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine (eCAM) is an international peer-reviewed, Open Access journal that seeks to understand the sources and to encourage rigorous research in this new, yet ancient world of complementary and alternative medicine.

Mass spectrometry in bioinorganic analytical chemistry

In a comparison study between the HPLC‐MS/MS and HPLC‐ICP MS determinations of a metallodrug in dog plasma samples, both methods could provide accurate and precise results. HPLC‐ICPMS offered advantages of extended linear range and 50‐times superior sensitivity (Smith et al., 2003).

US Patent for Compositions and methods for treatment of

This application claims the benefit of the filing of U.S. Provisional Patent Application Serial No. 60/142,346, entitled Compositions And Methods For Treatment Of Sexual Dysfunction, filed on Jun. 29, 1999, and U.S. Provisional Patent Application Serial No. 60/194,987, entitled Compositions And Nasal Delivery Methods For Treatment Of Sexual

US6794489B2 – Compositions and methods for treatment of

In use of Melanotan-II, significant erectile responses were observed, with 8 of 10 treated men developing clinically apparent erections, and with a mean duration of tip rigidity greater than 80% for 38 minutes with Melanotan-II compared to 3.0 minutes with a placebo (p=0.0045).